Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783125072> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2783125072 endingPage "875" @default.
- W2783125072 startingPage "865" @default.
- W2783125072 abstract "Aim Regorafenib is a multikinase inhibitor under investigation for use in neovascular age‐related macular degeneration. In this phase I study, regorafenib eye drops were administered to healthy volunteers to provide information on safety, tolerability and systemic exposure. Methods This was a single‐centre, randomized, double‐masked, parallel‐group, dose‐escalation, placebo‐controlled study. Subjects received regorafenib eye drops (30 mg ml −1 , 25 μl) as a 0.75 mg single dose (Cohort 1), 0.75 mg twice daily (bid) or thrice daily (tid) over 14 days (Cohorts 2 and 3, respectively), 1.5 mg tid unilaterally for 3 days, then bilaterally for up to 14 days (Cohort 4), or placebo. Plasma samples were taken to estimate systemic exposure. Safety and functional assessments were performed throughout the study. Results Thirty‐six subjects received regorafenib and 12 received placebo. Regorafenib was safe and well tolerated over the dose range. No pathological changes occurred in the anterior, vitreous or posterior eye compartments. Mild eyelid redness, oedema and conjunctival hyperaemia were observed across all regorafenib cohorts; these were comparable with the effects seen with placebo. Predominant symptoms were blurred vision in the active and placebo groups. Systemic safety evaluations showed no clinically relevant findings. Absolute systemic exposure after multiple administrations of regorafenib eye drops at a dose of 0.75 mg was 600–700‐fold lower than after multiple oral administration of 160 mg day −1 , the dose approved in cancer indications. Conclusion These results indicate a favourable safety and tolerability profile of regorafenib eye drops up to 30 mg ml −1 tid for use in clinical studies." @default.
- W2783125072 created "2018-01-26" @default.
- W2783125072 creator A5002836856 @default.
- W2783125072 creator A5011294471 @default.
- W2783125072 creator A5015179001 @default.
- W2783125072 creator A5026056908 @default.
- W2783125072 creator A5039438947 @default.
- W2783125072 creator A5056136043 @default.
- W2783125072 creator A5085514176 @default.
- W2783125072 creator A5089960296 @default.
- W2783125072 date "2018-03-01" @default.
- W2783125072 modified "2023-09-25" @default.
- W2783125072 title "Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers" @default.
- W2783125072 cites W1575205563 @default.
- W2783125072 cites W1898328784 @default.
- W2783125072 cites W1971274032 @default.
- W2783125072 cites W1980323556 @default.
- W2783125072 cites W1981537050 @default.
- W2783125072 cites W1992703244 @default.
- W2783125072 cites W1995469705 @default.
- W2783125072 cites W2037903265 @default.
- W2783125072 cites W2055370551 @default.
- W2783125072 cites W2086475585 @default.
- W2783125072 cites W2097409998 @default.
- W2783125072 cites W2102701614 @default.
- W2783125072 cites W2133627716 @default.
- W2783125072 cites W2766119667 @default.
- W2783125072 cites W2771328536 @default.
- W2783125072 cites W306945232 @default.
- W2783125072 cites W4233230329 @default.
- W2783125072 doi "https://doi.org/10.1111/bcp.13502" @default.
- W2783125072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5903260" @default.
- W2783125072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29315699" @default.
- W2783125072 hasPublicationYear "2018" @default.
- W2783125072 type Work @default.
- W2783125072 sameAs 2783125072 @default.
- W2783125072 citedByCount "7" @default.
- W2783125072 countsByYear W27831250722018 @default.
- W2783125072 countsByYear W27831250722019 @default.
- W2783125072 countsByYear W27831250722020 @default.
- W2783125072 countsByYear W27831250722021 @default.
- W2783125072 crossrefType "journal-article" @default.
- W2783125072 hasAuthorship W2783125072A5002836856 @default.
- W2783125072 hasAuthorship W2783125072A5011294471 @default.
- W2783125072 hasAuthorship W2783125072A5015179001 @default.
- W2783125072 hasAuthorship W2783125072A5026056908 @default.
- W2783125072 hasAuthorship W2783125072A5039438947 @default.
- W2783125072 hasAuthorship W2783125072A5056136043 @default.
- W2783125072 hasAuthorship W2783125072A5085514176 @default.
- W2783125072 hasAuthorship W2783125072A5089960296 @default.
- W2783125072 hasBestOaLocation W27831250721 @default.
- W2783125072 hasConcept C121608353 @default.
- W2783125072 hasConcept C126322002 @default.
- W2783125072 hasConcept C141071460 @default.
- W2783125072 hasConcept C142724271 @default.
- W2783125072 hasConcept C197934379 @default.
- W2783125072 hasConcept C204787440 @default.
- W2783125072 hasConcept C27081682 @default.
- W2783125072 hasConcept C2776248978 @default.
- W2783125072 hasConcept C2778375690 @default.
- W2783125072 hasConcept C42219234 @default.
- W2783125072 hasConcept C526805850 @default.
- W2783125072 hasConcept C71924100 @default.
- W2783125072 hasConceptScore W2783125072C121608353 @default.
- W2783125072 hasConceptScore W2783125072C126322002 @default.
- W2783125072 hasConceptScore W2783125072C141071460 @default.
- W2783125072 hasConceptScore W2783125072C142724271 @default.
- W2783125072 hasConceptScore W2783125072C197934379 @default.
- W2783125072 hasConceptScore W2783125072C204787440 @default.
- W2783125072 hasConceptScore W2783125072C27081682 @default.
- W2783125072 hasConceptScore W2783125072C2776248978 @default.
- W2783125072 hasConceptScore W2783125072C2778375690 @default.
- W2783125072 hasConceptScore W2783125072C42219234 @default.
- W2783125072 hasConceptScore W2783125072C526805850 @default.
- W2783125072 hasConceptScore W2783125072C71924100 @default.
- W2783125072 hasIssue "5" @default.
- W2783125072 hasLocation W27831250721 @default.
- W2783125072 hasLocation W27831250722 @default.
- W2783125072 hasLocation W27831250723 @default.
- W2783125072 hasOpenAccess W2783125072 @default.
- W2783125072 hasPrimaryLocation W27831250721 @default.
- W2783125072 hasRelatedWork W1966047811 @default.
- W2783125072 hasRelatedWork W2003042623 @default.
- W2783125072 hasRelatedWork W202460821 @default.
- W2783125072 hasRelatedWork W2035049801 @default.
- W2783125072 hasRelatedWork W2068849886 @default.
- W2783125072 hasRelatedWork W2109235243 @default.
- W2783125072 hasRelatedWork W2147606462 @default.
- W2783125072 hasRelatedWork W3023502736 @default.
- W2783125072 hasRelatedWork W3139841107 @default.
- W2783125072 hasRelatedWork W4308071420 @default.
- W2783125072 hasVolume "84" @default.
- W2783125072 isParatext "false" @default.
- W2783125072 isRetracted "false" @default.
- W2783125072 magId "2783125072" @default.
- W2783125072 workType "article" @default.